ROQUEFORT THERAPEUTICS PLC
Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.
ROQ | IL
Overview
Corporate Details
- ISIN(s):
- GB00BMDQ2T15
- LEI:
- 254900P4SISIWOR9RH34
- Country:
- United Kingdom
- Address:
- 85 Great Portland Street, W1W 7LT London
- Website:
- https://www.roquefortplc.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Roquefort Therapeutics plc is a biotechnology company focused on developing a portfolio of first-in-class medicines for hard-to-treat cancers. Its pipeline consists of five novel, patent-protected, pre-clinical anti-cancer programs targeting malignancies resistant to existing therapies within the high-growth immuno-oncology market. The company employs a scalable and cost-effective distributed R&D model, combining its in-house, state-of-the-art laboratory capabilities with a network of academic research partnerships. Founded in 2020, Roquefort Therapeutics is led by an experienced team with a proven track record in drug development, regulatory processes, and biotech transactions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-08 08:00 |
M&A Activity
Proposed Acquisition of Clinical Stage Company
|
English | 26.7 KB | ||
| 2025-07-07 08:00 |
Director's Dealing
Director/PDMR Shareholding
|
English | 24.3 KB | ||
| 2025-06-30 08:00 |
Director's Dealing
Director/PDMR Shareholding
|
English | 24.4 KB | ||
| 2025-06-27 08:00 |
M&A Activity
Lyramid SPA Extension
|
English | 14.1 KB | ||
| 2025-06-26 14:00 |
Declaration of Voting Results & Voting Rights Announcements
Results of AGM
|
English | 25.0 KB | ||
| 2025-06-02 08:00 |
Pre-Annual General Meeting Information
Notice of Annual General Meeting
|
English | 10.3 KB | ||
| 2025-05-23 08:00 |
Capital/Financing Update
Extension of Convertible Loan Notes
|
English | 11.9 KB | ||
| 2025-05-20 08:50 |
Annual Report (ESEF)
2024 Annual Report
|
English | 1.8 MB | ||
| 2025-05-20 08:50 |
Annual Report
2024 Annual Report
|
English | 3.9 MB | ||
| 2025-03-14 08:00 |
Capital/Financing Update
Private Placing and Conversion of CLNs
|
English | 14.5 KB | ||
| 2025-03-10 08:30 |
Board/Management Information
Board Changes
|
English | 14.4 KB | ||
| 2025-03-10 08:00 |
M&A Activity
Proposed Sale of Oncogeni Ltd
|
English | 13.5 KB | ||
| 2025-03-04 08:00 |
Regulatory News Service
Update on Sale of Lyramid
|
English | 15.0 KB | ||
| 2025-02-04 11:58 |
Director's Dealing
Director/PDMR Shareholding
|
English | 35.8 KB | ||
| 2025-02-03 08:00 |
Regulatory News Service
Share Purchase Agreement Signed - Sale of Lyramid
|
English | 21.5 KB |
Automate Your Workflow. Get a real-time feed of all ROQUEFORT THERAPEUTICS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for ROQUEFORT THERAPEUTICS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
